Samsung Bioepis said Wednesday that it has signed a memorandum of understanding with ATLATL Innovation Center, a China-based bioresearch platform, to expand its global open innovation efforts.
ATLATL Innovation Center is one of Asia’s largest biotech incubation platforms, supporting startups through shared laboratories, office space, and contract research organization (CRO) services across hubs including Beijing, Shanghai, Singapore, and Australia.
Samsung Bioepis’ laboratory (Courtesy of Samsung Bioepis)
Under the agreement, Samsung Bioepis will identify promising biotech startups and support their early-stage development by facilitating access to ATLATL’s infrastructure and enabling joint research.
This partnership marks Samsung Bioepis’ first open innovation collaboration with an overseas specialized institution, as it seeks to secure next-generation technologies across multiple therapeutic modalities.
Seo Min-jung, Executive Vice President and Head of Open Innovation at Samsung Bioepis, said global collaboration is critical to advancing biotech innovation.
“Global cooperation drives biotech innovation. This partnership will help accelerate the discovery and research of next-generation biotechnologies by leveraging advanced infrastructure and expertise.”
Lee Han-soo
댓글
0